Back to library
AestheticSubcutaneous
Gonadorelin (GnRH)
Also known as: GnRH · LHRH · Factrel
Synthetic decapeptide identical to endogenous gonadotropin-releasing hormone. Pulsatile dosing stimulates anterior pituitary release of LH and FSH, supporting endogenous testosterone production. Continuous or high-dose exposure paradoxically suppresses the axis via receptor desensitization.
At a glance
- Half-life
- 24 minutes
- Common route
- Subcutaneous
- Typical dose range
- 50–200mcg
- Stability (reconstituted)
- 14days refrigerated
Best timing
Pulsatile dosing critical — typically 2–3x daily in small doses, mimicking natural hypothalamic pulses. Continuous high dosing causes axis shutdown.
Contraindications
- Hormone-sensitive cancers (prostate, breast)
- Pregnancy
- Pituitary adenoma
- Known hypersensitivity to gonadorelin
Watch symptoms
- Local injection reactions
- Headache, mild nausea
- Initial androgen surge — possible mood or acne changes
- Suppression rather than stimulation if dosing pattern is wrong
- Risk of HPG axis disruption with prolonged use
Citations